Nexavar
NICE rejects Bayer’s liver cancer drug
May 26, 2010Sales and Marketing NICE, Nexavar, patient access scheme
Bayer’s liver cancer drug Nexavar has been rejected by NICE after it deemed the drug too costly for a marginal …
Nexavar shows promise in breast cancer
September 24, 2009Sales and Marketing Cancer, Nexavar, breast cancer
Bayer’s Nexavar has been shown to significantly extend progression-free survival in patients with advanced breast cancer in a new phase …
NICE criticised for rejection of kidney cancer drugs
August 27, 2009Research and Development, Sales and Marketing Kidney cancer, NICE, Nexavar
Three treatments for advanced kidney cancer have been rejected by NICE, sparking criticism from pharma companies and patient groups.The drugs …
NICE rejects Nexavar for liver cancer
May 7, 2009Research and Development, Sales and Marketing Bayer, NICE, Nexavar
NICE has rejected Nexavar as a treatment for liver cancer, saying it is not a cost-effective use of NHS resources. …
Nexavar fails in melanoma study
April 30, 2009Research and Development Bayer, Cancer, Nexavar
Onyx Pharmaceuticals and its development partner Bayer have stopped a phase II trial of Nexavar in patients with late-stage melanoma, …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
Coriolis Pharma appoints Teun van der Heide as CEO
